A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard<sup>®</sup> as an immunotherapeutic treatment for healthy Leishmania infantum-seropositive dogs.

Parasit Vectors · 2023 · PMC10552330 · PMID 37794502

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These differences were highly significant in low-seropositive dogs while, in medium- to high-seropositive dogs, disease development was similar in both groups.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.